Novartis AG
NYSE:NVSDrug Manufacturers - General
-$3.38 today
- Market cap
- $293.13B
- Beta
- 0.49
- P/E (TTM)
- 20.7
- EPS (TTM)
- $7.06
- Dividend yield
- 3.13%
Volume 2.75M
Average 1.56M
NVS Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Novartis AGNYSE: NVS
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow dips below year-ago levels
Q2 FY2026 financing cash flow of $2.03B (cash outflow) fell 61.0% year over year, behind the +102.8% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at -10.1% a year.
Context
- Financing cash flow amounted to 27.3% of revenue in FY2025, up 4.6 pp from a year earlier.
- Financing cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -61.0% toward the trailing-twelve-month pace of +102.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (14.94B) USD
- Year-over-year change
- -27.3%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (14.94B) | -27.3% |
| FY2024 | 2024-12-31 | (11.74B) | +17.8% |
| FY2023 | 2023-12-31 | (14.28B) | +30.6% |
| FY2022 | 2022-12-31 | (20.56B) | -26.4% |
| FY2021 | 2021-12-31 | (16.26B) | — |
Financing Cash Flow vs competitors
How NVS compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +102.8% is the 4th highest of 11, against a peer median of +11.1%.
- Financing cash flow amounts to 0.8% of revenue for NVS, versus a peer median of 14.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 24.19B DKK | +8.3% | -18.1% | 7.3% | |
| LTM Sep 2026 | $18.15B USD | +229.4% | -14.5% | 18.3% | |
| LTM Jun 2026 | $12.89B USD | -7.3% | -19.9% | 20.0% | |
| LTM Jun 2026 | $11.71B USD | +40.7% | -15.2% | 23.8% | |
| LTM Jun 2026 | €9.13B EUR | +1442.5% | +16.7% | 18.7% | |
| LTM Jun 2026 | $8.4B USD | -53.8% | -11.4% | 13.2% | |
| LTM Jun 2026 | $6.17B USD | +141.8% | -40.5% | 9.3% | |
| LTM Sep 2026 | $5.39B USD | +9.1% | +3.4% | 8.7% | |
| LTM Jun 2026 | $4.65B USD | +13.0% | +6.2% | 15.3% | |
| LTM Jun 2026 | £2.53B GBP | -29.6% | — | 7.6% | |
| LTM Jun 2026 | $472.2M USD | +102.8% | -10.1% | 0.8% | |
| Peer median (excluding NVS) | — | +11.1% | -14.5% | 14.2% | |
Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 22.91B | 6.05B | 8.57B | 11.94B | 14.06B |
| Depreciation & Amortization | 5.6B | 6.71B | 8.28B | 6.07B | 5.35B |
| Deferred Income Tax | 1.63B | 1.13B | 551M | 1.7B | (361.84M) |
| Stock-Based Compensation | 700M | 791M | 865M | 1.04B | 0 |
| Change in Working Capital | (73M) | (796M) | (369M) | (706M) | (3.08B) |
| Accounts Receivables | (352M) | (397M) | (1.5B) | (931M) | (1.13B) |
| Inventory | (102M) | (560M) | (546M) | (225M) | 34.17M |
| Accounts Payables | (111M) | (181M) | 479M | (105M) | (274.4M) |
| Other Working Capital | 492M | 342M | 1.2B | 555M | (1.71B) |
| Other Non-Cash Items | (15.68B) | 359M | (3.44B) | (2.43B) | 3.27B |
| Operating Cash Flow | 15.07B | 14.24B | 14.46B | 17.62B | 19.24B |
| Capital Expenditures | (2.56B) | (2.24B) | (2.75B) | (3.81B) | (1.56B) |
| Acquisitions (Net) | 20.46B | (864M) | (3.57B) | (3.83B) | (3.01B) |
| Purchases of Investments | (16.59B) | (34.81B) | (747M) | (3.65B) | (304.55M) |
| Sales of Investments | 2.74B | 39.49B | 11.6B | 3.7B | 2.19B |
| Other Investing Activities | (1.34B) | (1.43B) | (624M) | (2.38B) | 140.72M |
| Investing Cash Flow | 4.21B | 1.47B | 5.6B | (7.51B) | (4.9B) |
| Debt Repayment | (5.67B) | (2.59B) | (1.94B) | 4.39B | 2.72B |
| Common Stock Issued | 0 | 0 | 0 | 0 | 27.14M |
| Common Stock Repurchased | (3.06B) | (10.65B) | (8.72B) | (8.33B) | (9.26B) |
| Dividends Paid | (7.37B) | (7.51B) | (7.26B) | (7.62B) | (7.86B) |
| Other Financing Activities | (169M) | 181M | 3.63B | (177M) | (577.95M) |
| Financing Cash Flow | (16.26B) | (20.56B) | (14.28B) | (11.74B) | (14.94B) |
| Effect of Forex Changes | (266M) | (32M) | 100M | (298M) | 579.07M |
| Net Change in Cash | 2.75B | (4.89B) | 5.88B | (1.93B) | (24M) |
| Free Cash Flow | 12.52B | 12B | 11.71B | 13.81B | 17.69B |
Novartis AG
NYSE:NVS
Intrinsic Alpha fair value
Locked
Current Price
$155.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.